← Back to Alexion Pharmaceuticals

Revision of Alexion Pharmaceuticals

← Back to history

VH · · mediawikibotCreated by auto-bot V1

Rendered

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in 2020 revenues, used to treat hypophosphatasia; sebelipase alfa (Kanuma) with $117 million in 2020 revenues, used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa) with $78 million in 2020 revenues, used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide. from Wikipedia

American company

Wikitext diff vs parent

{{DISPLAYTITLE:Alexion Pharmaceuticals}}
Alexion Pharmaceuticals Inc.<small> from [https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals Wikipedia]</small>
{|
|+ 
|-
! Icon !! Service !! Username !!
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in 2020 revenues, used to treat hypophosphatasia; sebelipase alfa (Kanuma) with $117 million in 2020 revenues, used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa) with $78 million in 2020 revenues, used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.<small> from [https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals Wikipedia]</small>

{{SF|
{{Twt|AlexionPharma}}
{{Wb|https://alexion.com/|https:alexion.com}}
{{Yt|UClgBSounH8P9Lo22uaaZ0gw|Alexion Pharmaceuticals}}
|}
{{Wb|https://alexion.com/|alexion.com}}
{{Yt|UClgBSounH8P9Lo22uaaZ0gw|Alexion Pharmaceuticals, Inc.}}
}}
{{IDF|
{{Wd|Q204727}}
{{Isni|0000000404080730}}
}}

[[VHID]]:[https://verifiedhandles.com/vhid/62311669317 62311669317]
{{#subtitle: <big>American company</big>}}
{{VHID|62311669317}}{{#subtitle: <big>American company</big>}}